Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Compounds with high affinity for 5-HT1A and/or D2 receptors reported by E. Merck

June 7, 1996

CCD-3693 clinical trials scheduled

June 7, 1996

Bristol-Myers Squibb describes compounds with melatonergic properties

June 7, 1996

Pfizer reveals migraine treatment

June 7, 1996

Controlled-release oxycodone HCl now on U.S. shelves

June 7, 1996

More tachykinin antagonists described by Merck & Co.

June 7, 1996

Clinical trials on Diatide's Sn-117m DTPA

June 7, 1996

Tachykinin NK1 antagonists described by Ciba-Geigy

June 7, 1996

Production of recombinant human basic fibroblast growth factor covered by U.S. patent

May 31, 1996

Neurotrophic polypeptides disclosed by Children's Medical Center

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...